NURO VS CYCC Stock Comparison
Performance
NURO10/100
10/100
NURO returned -70.24% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
CYCC10/100
10/100
CYCC returned -69.77% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
NURO63/100
63/100
2 analysts offer 12-month price targets for NURO. Together, they have an average target of 0, the most optimistic target put NURO at 0 within 12-months and the most pessimistic has NURO at 0.
CYCC75/100
75/100
1 analysts offer 12-month price targets for CYCC. Together, they have an average target of 0, the most optimistic target put CYCC at 0 within 12-months and the most pessimistic has CYCC at 0.
Technicals
NURO36/100
36/100
NURO receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
CYCC14/100
14/100
CYCC receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
NURO100/100
100/100
NURO has missed earnings 0 times in the last 20 quarters.
CYCC10/100
10/100
CYCC has missed earnings 8 times in the last 20 quarters.
Profit
NURO10/100
10/100
Out of the last 20 quarters, NURO has had 1 profitable quarters and has increased their profits year over year on 0 of them.
CYCC10/100
10/100
Out of the last 20 quarters, CYCC has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
NURO51/100
51/100
NURO has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
CYCC48/100
48/100
CYCC has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
Dividend
NURO
"Dividend" not found for NURO
CYCC10/100
10/100
CYCC's most recent dividend was $0.08 per share, based on a share price of $0.34. It was a payout ratio of -2.36% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
NeuroMetrix, Inc. Common Stock Summary
Nasdaq / NURO
Healthcare
Medical - Devices
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Cyclacel Pharmaceuticals, Inc Summary
Nasdaq / CYCC
Healthcare
Biotechnology
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare NURO to other companies in the same or a similar industry.